Conduit Pharmaceuticals INC

CDT Equity Inc. has entered into a Securities Purchase Agreement to acquire a 4.76% stake in Sarborg Limited by issuing pre-funded warrants.

CDT Equity Inc. announced the issuance of 32,110 shares of common stock to a service provider for consulting services, utilizing an exemption from registration requirements.

CDT Equity Inc. is implementing a 1-for-10 reverse stock split to maintain compliance with Nasdaq's bid-price rule, effective July 17, 2026.

CDT Equity Inc. has amended its loan agreement and convertible note, delaying the start of weekly installment payments.

CDT Equity Inc. has appointed Carr, Riggs & Ingram, L.L.C. as its new independent registered public accounting firm, replacing CBIZ CPAs P.C.

CDT Equity Inc. has entered into a new $1.46 million loan facility with J.J. Astor & Co. to support working capital while eliminating over $6.3 million in legacy debt obligations.

CDT Equity Inc. reported a net loss for Q1 2026, with significant strategic investments and ongoing liquidity concerns, while also detailing progress in R&D and partnerships.

CDT Equity Inc. reported a net loss of $7.1 million for Q3 2025 and $17.9 million for the nine months ended September 30, 2025, while advancing its data-driven biotech and digital asset treasury management strategy.

CDT Equity Inc. reported a wider net loss for the first half of 2025 despite significant capital raises, as it pivots to an AI-driven biotech development strategy and expands its asset portfolio.

CDT Equity Inc. restated its Q1 2025 financial results due to reclassification errors, reporting increased net losses and significant liquidity concerns, while actively pursuing strategic AI partnerships and asset development.

Conduit Pharmaceuticals reports a net loss of $5.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Conduit Pharmaceuticals reported a net loss of $6.5 million for Q3 2024 and faces substantial doubt about its ability to continue as a going concern due to significant operating losses and limited cash reserves.

CDT Equity Inc. files its annual report detailing its securities, corporate governance, financial metrics, and future outlook, highlighting ongoing development and strategic partnerships.

Conduit Pharmaceuticals details its securities, governance structure, and risk factors in its annual 10-K filing, highlighting its focus on clinical asset development and AI integration.

Conduit Pharmaceuticals outlines its capital structure, including common and preferred stock, and various warrants in its latest 10-K filing.

CDT Equity Inc. reports significant insider transactions including stock purchases and warrant exercises by CEO Andrew Regan and related entities.

Mark Taylor, a director and 10% owner of CDT Equity Inc., significantly increased his indirect beneficial ownership through the cashless exercise of pre-funded warrants.

CDT Equity Inc. acquired shares of Sarborg Limited from Director Chele Chiavacci Farley and other stockholders, issuing common stock and pre-funded warrants.

CDT Equity Inc. issued common stock and pre-funded warrants to Corvus Capital Ltd. as consideration for the acquisition of Conduit Pharmaceuticals Limited.

CDT Equity Inc. granted its Chief Executive Officer and Director, Andrew Regan, 1,120,000 shares of common stock as compensation for his services.

CDT Equity Inc. CFO and Director James Bligh was granted 480,000 shares of restricted common stock, valued at approximately $329,424, which vested immediately under the company's incentive plan.

CDT Equity Inc. is seeking stockholder approval for several critical proposals, including significant share issuances, an equity line of credit, a reverse stock split, an increase in authorized shares, and redomestication to the Cayman Islands.

Conduit Pharmaceuticals Inc. announced its 2025 virtual annual meeting to elect directors, ratify auditors, and approve a significant increase in its stock incentive plan, while detailing recent management changes, related party transactions, and a new licensing agreement with AstraZeneca.

Conduit Pharmaceuticals is asking stockholders to approve a reverse stock split, ranging from 1-for-2 to 1-for-100 (and up to 1-for-250 in aggregate), to potentially maintain its Nasdaq listing and attract investors.

Conduit Pharmaceuticals is holding a special virtual meeting on January 9, 2025, to seek stockholder approval for the issuance of common stock related to warrant exercises and the conversion of promissory notes.

Conduit Pharmaceuticals files a supplement to its proxy statement to correct errors regarding director independence and audit committee composition, aiming to comply with Nasdaq listing standards by December 18, 2024.

Conduit Pharmaceuticals Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Conduit Pharmaceuticals enters into a licensing agreement with AstraZeneca, gaining exclusive rights to develop and commercialize certain pharmaceutical compounds in exchange for upfront payments, equity issuance, and future revenue sharing.

Conduit Pharmaceuticals files an S-1 registration statement for the resale of up to 22,004,465 shares of common stock issued to AstraZeneca and Nirland Limited.

Corvus Capital Ltd. and Andrew Regan have amended their Schedule 13D filing for CDT Equity Inc., reporting increased beneficial ownership to 5.3% and 5.4% respectively, following warrant exercises and open market purchases.

Mark Taylor and his entities, Prospect Capital and Prospect Finance, significantly increase their stake in CDT Equity Inc. to 43.79% following a strategic acquisition and warrant exercise.

Corvus Capital Ltd. increased its beneficial ownership in CDT Equity Inc. to 12.2% by acquiring a subsidiary and receiving shares and pre-funded warrants as part of a $7 million settlement.

Andrew Regan, a director and officer of CDT Equity Inc., significantly increased his beneficial ownership to 13.3% after receiving 1.12 million shares as compensation.

Conduit Pharmaceuticals Inc. has filed an amended Schedule 13D, revealing significant changes in beneficial ownership, detailing two recent reverse stock splits, and announcing a new Joint Development Agreement with related party Manoira Corporation.

A group of investment entities led by Ascent Partners and Eagle Claw Corp. has reported a 9.9% beneficial ownership stake in CDT Equity Inc. following an internal management reorganization.

Nirland Limited and affiliated entities filed a Schedule 13G disclosing a 1.6% beneficial ownership stake in CDT Equity Inc. common stock.

Sarborg Ltd has filed an amended Schedule 13G, disclosing a 4.0% beneficial ownership stake in CDT Equity Inc. following a recent reverse stock split.

A group including A.G.P. / Alliance Global Partners, LLC, Alliance Global Holdings, Inc., and several individuals, has disclosed a beneficial ownership of 9.77% of Conduit Pharmaceuticals Inc.'s common stock.

Sarborg Ltd has filed a Schedule 13G, reporting a 16.4% passive beneficial ownership stake in Conduit Pharmaceuticals Inc. as of March 31, 2025.

AstraZeneca PLC and its subsidiary AstraZeneca AB have filed an amended Schedule 13G, reporting a 1.1% passive beneficial ownership stake in Conduit Pharmaceuticals Inc.